Posted On: 08/12/2016 9:17:43 AM
Post# of 83
The Company has now Cash untill mid 2018 excluding Upfront Payments from new Partnerships and Product Revenues . Partnerdeal news and Phase 1 Results of their Alzheimer Drug coming within 6 Weeks . Market Cap still way below $50 Million which is still a big Joke .
from yesterdays 2Q Results
http://www.intelgenx.com/investors/press-rele...fault.aspx
Continued late-stage discussions with global pharmaceutical companies for multiple products with the potential goal of concluding a definitive agreement to be finalized in the third quarter of 2016
Initiated a phase 1 study of Montelukast for the treatment of degenerative diseases of the brain, such as: mild cognitive impairment and Alzheimers disease, the most prominent form of dementia. IntelGenx expects results from the phase 1 trial to be available in September 2016.
from yesterdays 2Q Results
http://www.intelgenx.com/investors/press-rele...fault.aspx
Continued late-stage discussions with global pharmaceutical companies for multiple products with the potential goal of concluding a definitive agreement to be finalized in the third quarter of 2016
Initiated a phase 1 study of Montelukast for the treatment of degenerative diseases of the brain, such as: mild cognitive impairment and Alzheimers disease, the most prominent form of dementia. IntelGenx expects results from the phase 1 trial to be available in September 2016.
(0)
(0)Scroll down for more posts ▼
